Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | CCNH | P51946 | 1/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108168 | 1.00 | JAK2 (0.55) | JAK2JAK1MAP3K14CCNT1CCNK | |
| SCHEMBL517461 | 0.85 | RPS6KA5 (0.66) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL29613520 | 0.85 | RPS6KA5 (0.66) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL21628998 | 0.83 | MAP3K14 (0.52) | JAK2JAK1MAP3K14CCNT1CCNK | |
| SCHEMBL30554763 | 0.83 | MAP3K14 (0.52) | JAK2JAK1MAP3K14CCNT1CCNK | |
| SCHEMBL23152046 | 0.83 | CLK1 (0.71) | CCNT1CCNKCDK9CDK12RPS6KA5 | |
| SCHEMBL16075920 | 0.83 | CLK1 (0.71) | JAK2JAK1MAP3K14CCNT1CCNK | |
| SCHEMBL22510124 | 0.83 | CDK5 (0.56) | MAP3K14RPS6KA5CLK1CDK5CDK5R1 | |
| SCHEMBL518282 | 0.83 | CDK5 (0.49) | RPS6KA5CLK1CDK5CDK5R1PDGFRB | |
| SCHEMBL517759 | 0.83 | CCNT1 (0.52) | MAP3K14CCNT1CCNKCDK9CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| CN-112469715-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| CN-116693506-A | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2023-09-05 | — | — | CN | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| EP-4086246-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS AS EGFR MODULATORS | AstraZeneca AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | DPYD, TYMS, TYMP | JAK2 2276/4885JAK1 1230/4885MAP3K14 2292/4885 |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | JAK2 26/4885JAK1 255/4885MAP3K14 833/4885 |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | JAK2 144/4885JAK1 251/4885MAP3K14 34/4885 |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | JAK2 2276/4885JAK1 1230/4885MAP3K14 2292/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | JAK2 26/4885JAK1 255/4885MAP3K14 833/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | JAK2 26/4885JAK1 255/4885MAP3K14 833/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | JAK2 196/4885JAK1 124/4885MAP3K14 345/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | JAK2 26/4885JAK1 255/4885MAP3K14 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.